J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
January 6, 2022; 5:02 PM EST
(Reuters) – Johnson & Johnson (JNJ.N) said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
Vials labeled “COVID-19 Coronavirus Vaccine” and syringe are seen in front of displayed Johnson & Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration
The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc (PFE.N) and BioNTech’s (22UAy.DE) as well as Moderna (MRNA.O).
No waning of protection was found for ICU admissions for all the three vaccines, J&J said.
The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
